2011-Irbesartan in Patients with Atrial Fibrillation外文电子书籍.pdfVIP

T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Irbesartan in Patients with Atrial Fibrillation The ACTIVE I Investigators* A bs tr ac t Background The members of the writing group (Salim The risk of cardiovascular events among patients with atrial fibrillation is high. Yusuf, M.B., B.S., D.Phil., Jeff S. Healey, We evaluated whether irbesartan, an angiotensin-receptor blocker, would reduce M.D., Janice Pogue, M.Sc., Susan Chro- this risk. lavicius, R.N., Marcus Flather, M.B., B.Ch., Robert G. Hart, M.D., Stefan H. Hohn- loser, M.D., Campbell D. Joyner, M.D., Methods Marc A. Pfeffer, M.D., and Stuart J. Con- nolly, M.D.), assume responsibility for the We randomly assigned patients with a history of risk factors for stroke and a systolic overall content and integrity of the arti- blood pressure of at least 110 mm Hg to receive either irbesartan at a target dose of cle. Address reprint requests to Dr. Yusuf 300 mg once daily or double-blind placebo. These patients were already enrolled in at the Population Health Research Insti- tute, David Braley Cardiac, Vascular and one of two trials (of clopidogrel plus aspirin versus aspirin alone or versus oral anti- Stroke Research Institute, Hamilton Health coagulants). The first coprimary outcome was stroke, myocardial infarction, or death Sciences and McMaster University, 237 from vascular causes; the second was this composite outcome plus hospitalization Barton St. East, Hamilton, ON L8L 2X2,